Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Morgan Stanley Lowers Price Target on Certara to $16 From $21, Keeps Equalweight Rating
Certara's Mixed Financial Performance Leads to Hold Rating Amid Market Fluctuations
Certara Price Target Cut to $18.00/Share From $19.00 by Baird
Certara Analyst Ratings
Certara Stock Rated 'Hold' Amid Mixed Financial Performance and Market Expectations
UBS Adjusts Certara Price Target to $16 From $20, Maintains Neutral Rating
Bank of America Securities Reaffirms Their Buy Rating on Certara (CERT)
Barclays Maintains Certara(CERT.US) With Hold Rating, Maintains Target Price $16
Certara (CERT) Receives a Hold From Barclays
KeyBanc Adjusts Price Target on Certara to $20 From $23, Maintains Overweight Rating
Certara Analyst Ratings
Keybanc Maintains Overweight on Certara, Lowers Price Target to $20
Certara Analyst Ratings
Certara (CERT) Gets a Hold From Barclays
Market Perform Rating for Certara Amid Strategic Acquisition and Mixed Financial Outlook
Barclays Lowers Price Target on Certara to $16 From $18, Maintains Equalweight Rating
Certara Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Certara Analyst Maintains Hold Rating Amid Mixed Financial Performance and Strategic Developments